<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" id="no-js"><!-- InstanceBegin template="/Templates/ContentPage_Standard.dwt" codeOutsideHTMLIsLocked="false" -->

<head>
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
<!-- InstanceBeginEditable name="title-tag" -->
<title>CDC - MDRO Guideline:Prevent Transmission - HICPAC</title>
<!-- InstanceEndEditable --><!-- InstanceBeginEditable name="meta-data" -->
<meta name="Keywords" 		content="" />
<meta name="DC.Subject" 	content="" />
<meta name="DC.Language" 	scheme="ISO 639-2" content="eng" />
<meta http-equiv="X-UA-Compatible" content="IE=EmulateIE7" />
<!-- InstanceEndEditable --><!-- InstanceParam name="class" type="text" value="secondTier" --><!-- InstanceParam name="localFilesPath" type="text" value="/hicpac/" --><!-- InstanceParam name="content" type="boolean" value="true" --><!-- InstanceParam name="optionSpanish" type="boolean" value="false" --><!-- InstanceParam name="optionalFeatures" type="boolean" value="false" --><!-- InstanceParam name="optionalBreadCrumbs" type="boolean" value="false" --><!-- InstanceParam name="OptionalLocalSearch" type="boolean" value="false" --><!-- InstanceParam name="OptionalLocalA-Z" type="boolean" value="false" --><!-- InstanceParam name="optionalExtra" type="boolean" value="false" --><!-- InstanceParam name="JqueryUI" type="boolean" value="false" --><!-- InstanceParam name="JqueryUiAccordion" type="boolean" value="false" --><!-- InstanceParam name="JqueryUiCarousel" type="boolean" value="false" --><!-- InstanceParam name="JqueryUiDatePicker" type="boolean" value="false" --><!-- InstanceParam name="JqueryUiTabs" type="boolean" value="false" --><!-- InstanceParam name="dojoLibrary" type="boolean" value="false" -->

<meta http-equiv="content-type" content="text/html; charset=utf-8" />

<meta name="template.version" content="2.7.1.3" />
<!-- @package: TemplatePackage 'B' @version: "2.7.1.3" -->
<style type="text/css" media="screen">empty{color:#000};@import "https://hicpac//local/B/css/designview/designTime.css"/**/;</style>
<link rel="stylesheet" href="../../TemplatePackage/css/B/reset.css" type="text/css" media="screen" />
<link rel="stylesheet" href="../../TemplatePackage/css/B/newMods.css" type="text/css" media="screen" />
<link rel="stylesheet" href="../../TemplatePackage/css/B/print.css" type="text/css" media="print" />

<!-- compliance patch for microsoft browsers -->
<!--[if IE 6]>
<link rel="stylesheet" type="text/css" href="/TemplatePackage/css/B/ie6_fixes.css" />
<![endif]-->

<!--[if IE 7]>
<link rel="stylesheet" type="text/css" href="/TemplatePackage/css/B/ie7_fixes.css" />
<![endif]-->

<!--[if IE 8]>
<link rel="stylesheet" type="text/css" href="/TemplatePackage/css/B/ie8_fixes.css" />
<![endif]-->
<!-- /end compliance patch for microsoft browsers -->
<!-- JS below -->
<script type="text/javascript">(function(H){H.id=H.id.replace('no-','')})(document.documentElement)</script>
<script type="text/javascript" src="../../TemplatePackage/js/B/jquery.js"></script>
<script type="text/javascript" src="../../TemplatePackage/js/B/jquery.watermark.js"></script>
<script type="text/javascript" src="../../TemplatePackage/js/B/common.js"></script>
<script type="text/javascript" src="../../TemplatePackage/js/B/startup.js"></script>
<script type="text/javascript" src="../../TemplatePackage/js/B/socialMedia.js"></script>
<script type="text/javascript" src="../../TemplatePackage/js/B/blocks-ie.js"></script>
<script type="text/javascript" src="../../TemplatePackage/js/B/video.js"></script>
<script type="text/javascript" src="../../TemplatePackage/js/B/navScripts.js"></script>
<script type="text/javascript" src="../../TemplatePackage/js/B/govdelivery.js"></script>
<script type="text/javascript" src="../../TemplatePackage/js/B/anchor.js"></script>
<script type="text/javascript" src="../../TemplatePackage/js/B/syndicateThisPage.js"></script>
<script type="text/javascript" src="../../TemplatePackage/js/B/css-include.js"></script>
<script type="text/javascript" src="../../TemplatePackage/3.0/js/libs/moment/moment.min.js"></script>

<!-- compliance patch for microsoft browsers -->
<!--[if IE 6]>
<script type="text/javascript" src="/TemplatePackage/js/B/pngfix.js"></script>
<script type="text/javascript" src="/TemplatePackage/js/B/blocks-ie6.js"></script>
<![endif]-->

<!--[if lte IE 8]>
<script type="text/javascript" src="/TemplatePackage/js/B/jquery.curvycorners.js"></script>
<![endif]-->

<script type="text/javascript" src="../../TemplatePackage/js/B/cdc-gridCompatibility.js"></script>

<link rel="shortcut icon" href="../../TemplatePackage/images/home/favicon.ico" />
<link rel="home" href="../../index.html" title="Home" />

<!-- Begin Survey scripts -->
<script type="text/javascript" src="../../JScript/foresee/foresee-trigger.js"></script>
<script type="text/javascript" src="../../JScript/foresee-variables.js"></script>
<!-- End Survey scripts -->

<!-- InstanceBeginEditable name="local-css" -->
<style type="text/css" media="all">
@import "../local/B/css/local.css"/**/;
</style>
<script type="text/javascript" src="http://www.cdc.gov/news/scripts/govdelivery.js"></script>
<!--[if IE]>
<script defer language="javascript" type="text/javascript">
		var cdcLeftNav = new CDC.LeftNav("nav-primary");
		cdcLeftNav.render();
</script>
<![endif]-->
<!--[if ! IE]><!-->
<script language="javascript" type="text/javascript">
$().ready(function(){
		
		var cdcLeftNav = new CDC.LeftNav("nav-primary", location.pathname, true, true);
		cdcLeftNav.render();

});
</script>
<!--<![endif]-->

<!-- InstanceEndEditable -->
</head>
<body id="contentPageStandard" class="secondTier secondTier v270">

<div id="skipmenu">
	<a href="mdro_5.html#searchBox" class="skippy" title="Skip to search">Skip directly to search</a>
	<a href="mdro_5.html#az" class="skippy" title="Skip to A to Z list">Skip directly to A to Z list</a>
	<a href="mdro_5.html#nav" class="skippy" title="Skip to navigation">Skip directly to navigation</a>
	<a href="mdro_5.html#content-main" class="skippy" title="Skip to content">Skip directly to site content</a>
	<a href="mdro_5.html#content-secondary" class="skippy" title="Skip to page options">Skip directly to page options</a>
</div>
<div id="wrapper">
	<div id="wrapper-inner">
		<div id="branding">
			<span id="homeward"><a href="../../index.html" title="Return to the CDC Home Page">CDC Home</a></span>
<div id="branding-logo">
	<div id="branding-logoImage"><img src="../../TemplatePackage/images/cdcHeaderLogo.gif" width="470" height="47" alt="CDC. Centers for Disease Control and Prevention. CDC 24/7: Saving Lives. Protecting People." border="0" /><a href="../../index.html" title="CDC 24/7: Saving Lives. Protecting People.&trade;"><span>CDC 24/7: Saving Lives. Protecting People.&trade;</span></a></div>

				<div id="searchForm" class="searchResize"><a name="search"></a>
		<form id="searchCDC" method="get" action="https://search.cdc.gov/search">
			<fieldset>
				<div id="cdc-Query">
					<label for="searchBox" class="overlabel search">Search The CDC</label>
					<input id="searchBox" class="searchBox" name="query" maxlength="256" type="text" />
				</div>
				<div id="cdc-Submit">
					<!-- label for="searchButton" class="searchButton">Search Button</label -->
					<input id="searchButton" class="searchButton" src="../../TemplatePackage/images/home/search_button.gif" name="searchButton" alt="Search" type="image" />
					<input name="action" value="search" type="hidden" />
				</div>
				<input type="hidden" name="utf8" value="&#x2713;"/>
				<input type="hidden" name="affiliate" value="cdc-main"/>
			</fieldset>
		</form>
	</div>
			</div>
<noscript>
<div class="noscript"> Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: <a href="../../Other/about_cdcgov.html" title="Browser requirements for CDC.gov">About CDC.gov</a>.</div>
</noscript>
<!--<div id="emergency-alert">
<h1></h1> 
<p></p>
<a href="#"></a>
</div>-->
		</div>
		
		<div id="content">
			<div id="topic-title"><!-- InstanceBeginEditable name="topic-title" -->
			<h2><a href="../index.html">Healthcare Infection Control Practices Advisory Committee (HICPAC)</a></h2>
			<!-- InstanceEndEditable -->
			</div>
			<div id="content-inner">
				<!-- ########## BREADCRUMBS START HERE ########## -->
				<!-- InstanceBeginEditable name="breadcrumbs" -->
			<div id="breadBox">
	<ul id="breadcrumbs">
		<li style="display:none;"></li>
	</ul>
</div>
			<!-- InstanceEndEditable -->
				<div id="socialMediaContainer">
	<div class="share_container noLinking">
	 	<a class="share_button_facebook" title="Facebook" href="mdro_5.html#"><span id="share_facebook" class="facebookRecommend"></span></a>
	 	<a class="share_button_twitter" title="Twitter" href="mdro_5.html#"><span id="share_twitter" class="twitterTweet"></span></a>
		<a class="share_button noLinking" href="mdro_5.html#socialMediaContainer"><img src="../../TemplatePackage/images/social/sm-plus.gif" alt="Share" /><span class="shareButtonEn">Share</span><span class="shareButtonEs">Compartir</span></a>
	</div>
</div>

				<div id="content-main">
					<div class="main-inner">
						<!-- InstanceBeginEditable name="content-main" -->
                 
                   
                   
                  <h1>V. Prevention of transmission of Multidrug Resistant Organisms</h1>


<p>The CDC/HICPAC system for categorizing recommendations is as follows:</p>
<p>
<strong>Category IA</strong> Strongly recommended for implementation and strongly supported by welldesigned
experimental, clinical, or epidemiologic studies.</p>
<p>  <strong>Category IB </strong>Strongly recommended for implementation and supported by some
  experimental, clinical, or epidemiologic studies and a strong theoretical rationale. </p>
<p><strong>Category IC</strong> Required for implementation, as mandated by federal and/or state regulation
  or standard. </p>
<p><strong>Category II </strong>Suggested for implementation and supported by suggestive clinical or
  epidemiologic studies or a theoretical rationale. </p>
<p><strong>No recommendation</strong> Unresolved issue. Practices for which insufficient evidence or no
  consensus regarding efficacy exists.</p>
<p>&nbsp;</p>








<ul class="articleSubItems">
  <li>V.A.&nbsp;&nbsp;&nbsp;General recommendations for all healthcare settings independent of the prevalence
of multidrug resistant organism (MDRO) infections or the population served.
    <ul>
      <li>V.A.1.&nbsp;&nbsp;&nbsp;Administrative measures
        <ul>
          <li>V.A.1.a.&nbsp;&nbsp;&nbsp;Make MDRO prevention and control an organizational patient safety
            priority.(<a href="mdro_reference.html#3">3</a>, <a href="mdro_reference.html#146">146</a>, <a href="mdro_reference.html#151">151</a>, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#182">182</a>, <a href="mdro_reference.html#185">185</a>, <a href="mdro_reference.html#194">194</a>, <a href="mdro_reference.html#205">205</a>, <a href="mdro_reference.html#208">208</a>, <a href="mdro_reference.html#210">210</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#327">327</a>, <a href="mdro_reference.html#328">328</a>)
            Category IB</li>
          <li>V.A.1.b.&nbsp;&nbsp;&nbsp;Provide administrative support, and both fiscal and human resources, to
            prevent and control MDRO transmission within the healthcare organization
            (<a href="mdro_reference.html#3">3</a>, <a href="mdro_reference.html#9">9</a>, <a href="mdro_reference.html#146">146</a>, <a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#182">182</a>-184, <a href="mdro_reference.html#208">208</a>, <a href="mdro_reference.html#328">328</a>, <a href="mdro_reference.html#329">329</a>) Category IB </li>
          <li>V.A.1.c.&nbsp;&nbsp;&nbsp;In healthcare facilities without expertise for analyzing epidemiologic data,
            recognizing MDRO problems, or devising effective control strategies (e.g.,
            small or rural hospitals, rehabilitation centers, long-term care facilities
            [LTCFs], freestanding ambulatory centers), identify experts who can
            provide consultation as needed.(151, 188) Category II </li>
          <li>V.A.1.d.&nbsp;&nbsp;&nbsp;Implement systems to communicate information about reportable MDROs
            [e.g., VRSA, VISA, MRSA, Penicillin resistant S. pneumoniae(PRSP)] to
            administrative personnel and as required by state and local health
            
            authorities (www.cdc.gov/epo/dphsi/nndsshis.htm). Refer to websites for
            updated requirements of local and state health departments. Category II/IC</li>
          <li> V.A.1.e.&nbsp;&nbsp;&nbsp;Implement a multidisciplinary process to monitor and improve healthcare
            personnel (HCP) adherence to recommended practices for Standard and
            Contact Precautions(<a href="mdro_reference.html#3">3</a>, <a href="mdro_reference.html#105">105</a>, <a href="mdro_reference.html#182">182</a>, <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#189">189</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#273">273</a>, <a href="mdro_reference.html#312">312</a>, 330). Category
            IB </li>
          <li>V.A.1.f.&nbsp;&nbsp;&nbsp;Implement systems to designate patients known to be colonized or infected
            with a targeted MDRO and to notify receiving healthcare facilities and
            personnel prior to transfer of such patients within or between facilities.(87,
            151) Category IB </li>
          <li>V.A.1.g.&nbsp;&nbsp;&nbsp;Support participation of the facility or healthcare system in local, regional,
            and national coalitions to combat emerging or growing MDRO
            problems.(41, <a href="mdro_reference.html#146">146</a>, <a href="mdro_reference.html#151">151</a>, 167, <a href="mdro_reference.html#188">188</a>, <a href="mdro_reference.html#206">206</a>, <a href="mdro_reference.html#207">207</a>, <a href="mdro_reference.html#211">211</a>, 331). Category IB </li>
          <li>V.A.1.h.&nbsp;&nbsp;&nbsp;Provide updated feedback at least annually to healthcare providers and
            administrators on facility and patient-care-unit trends in MDRO infections.
            Include information on changes in prevalence or incidence of infection,
            results of assessments for system failures, and action plans to improve
            adherence to and effectiveness of recommended infection control practices
            to prevent MDRO transmission.(<a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#159">159</a>, <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#204">204</a>, <a href="mdro_reference.html#205">205</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#312">312</a>,
            <a href="mdro_reference.html#332">332</a>) Category IB</li>
        </ul>
      </li>
      <li>V.A.2.&nbsp;&nbsp;&nbsp;Education and training of healthcare personnel
        <ul>
          <li>V.A.2.a.&nbsp;&nbsp;&nbsp;Provide education and training on risks and prevention of MDRO
            transmission during orientation and periodic educational updates for
            healthcare personnel; include information on organizational experience
            with MDROs and prevention strategies.(<a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#173">173</a>, <a href="mdro_reference.html#176">176</a>, <a href="mdro_reference.html#189">189</a>, <a href="mdro_reference.html#190">190</a>,
            <a href="mdro_reference.html#203">203</a>, <a href="mdro_reference.html#204">204</a>, <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#242">242</a>,  <a href="mdro_reference.html#330">330</a>, <a href="mdro_reference.html#333">333</a>, 334) Category IB</li>
        </ul>
      </li>
      <li>V.A.3.&nbsp;&nbsp;&nbsp;Judicious use of antimicrobial agents. The goal of the following
        recommendations is to ensure that systems are in place to promote optimal
        treatment of infections and appropriate antimicrobial use.
        <ul>
          <li>V.A.3.a.&nbsp;&nbsp;&nbsp;In hospitals and LTCFs, ensure that a multidisciplinary process is in place
            to review antimicrobial utilization, local susceptibility patterns
            36
            (antibiograms), and antimicrobial agents included in the formulary to foster
            appropriate antimicrobial use.(209, <a href="mdro_reference.html#212">212</a>, <a href="mdro_reference.html#214">214</a>, <a href="mdro_reference.html#215">215</a>, <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#242">242</a>, 254, 334-<a href="mdro_reference.html#339">339</a>)
            Category IB</li>
          <li>V.A.3.b.&nbsp;&nbsp;&nbsp;Implement systems (e.g., computerized physician order entry, comment in
            microbiology susceptibility report, notification from a clinical pharmacist or
            unit director) to prompt clinicians to use the appropriate antimicrobial agent
            and regimen for the given clinical situation.(156, 157, <a href="mdro_reference.html#161">161</a>, <a href="mdro_reference.html#166">166</a>, <a href="mdro_reference.html#174">174</a>, <a href="mdro_reference.html#175">175</a>,
            <a href="mdro_reference.html#212">212</a>, <a href="mdro_reference.html#214">214</a>, <a href="mdro_reference.html#218">218</a>, 254, 334, 335, 337, 340-346) Category IB
            <ul>
              <li>V.A.3.b.i.&nbsp;&nbsp;&nbsp;Provide clinicians with antimicrobial susceptibility reports and
                analysis of current trends, updated at least annually, to guide
                antimicrobial prescribing practices.(342, 347) Category IB</li>
              <li>V.A.3.b.ii.&nbsp;&nbsp;&nbsp;In settings that administer antimicrobial agents but have limited
                electronic communication system infrastructures to implement
                physician prompts (e.g., LTCFs, home care and infusion
                companies), implement a process for appropriate review of
                prescribed antimicrobials. Prepare and distribute reports to
                prescribers that summarize findings and provide suggestions for
                improving antimicrobial use. (342, 348, 349) Category II</li>
            </ul>
          </li>
        </ul>
      </li>
      <li>V.A.4.&nbsp;&nbsp;&nbsp;Surveillance
        <ul>
          <li>V.A.4.a.&nbsp;&nbsp;&nbsp;In microbiology laboratories, use standardized laboratory methods and
            follow published guidance for determining antimicrobial susceptibility of
            targeted (e.g., MRSA, VRE, MDR-ESBLs) and emerging (e.g., VRSA,
            MDR-Acinetobacter baumannii) MDROs.(<a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#177">177</a>, <a href="mdro_reference.html#190">190</a>, <a href="mdro_reference.html#193">193</a>, <a href="mdro_reference.html#209">209</a>, 254,
            347, 350-353) Category IB </li>
          <li>V.A.4.b.&nbsp;&nbsp;&nbsp;In all healthcare organizations, establish systems to ensure that clinical
            microbiology laboratories (in-house and out-sourced) promptly notify
            infection control staff or a medical director/ designee when a novel
            resistance pattern for that facility is detected.(<a href="mdro_reference.html#9">9</a>, 22, <a href="mdro_reference.html#154">154</a>, 162, 169)
            Category IB </li>
          <li>V.A.4.c.&nbsp;&nbsp;&nbsp;In hospitals and LTCFs, develop and implement laboratory protocols for
            storing isolates of selected MDROs for molecular typing when needed to
            
            confirm transmission or delineate the epidemiology of the MDRO within the
            healthcare setting.(<a href="mdro_reference.html#7">7</a>, 8, <a href="mdro_reference.html#38">38</a>, 140, 153, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#187">187</a>, <a href="mdro_reference.html#190">190</a>, <a href="mdro_reference.html#208">208</a>, <a href="mdro_reference.html#217">217</a>, 354, 355)
            Category IB </li>
          <li>V.A.4.d.&nbsp;&nbsp;&nbsp;Prepare facility-specific antimicrobial susceptibility reports as
            recommended by the Clinical and Laboratory Standards Institute (CLSI)
            (www.phppo.cdc.gov/dls/master/default.aspx); monitor these reports for
            evidence of changing resistance patterns that may indicate the emergence
            or transmission of MDROs.(347, 351, 356, 357) Category IB/IC
            <ul>
              <li>V.A.4.d.i.&nbsp;&nbsp;&nbsp;In hospitals and LTCFs with special-care units (e.g., ventilatordependent,
                ICU, or oncology units), develop and monitor unitspecific
                antimicrobial susceptibility reports.(358-361) Category IB </li>
              <li>V.A.4.d.ii.&nbsp;&nbsp;&nbsp;Establish a frequency for preparing summary reports based on
                volume of clinical isolates, with updates at least annually.(347, 362)
                Category II/IC</li>
              <li> V.A.4.d.iii.&nbsp;&nbsp;&nbsp;In healthcare organizations that outsource microbiology laboratory
                services (e.g., ambulatory care, home care, LTCFs, smaller acute
                care hospitals), specify by contract that the laboratory provide either
                facility-specific susceptibility data or local or regional aggregate
                susceptibility data in order to identify prevalent MDROs and trends
                in the geographic area served.(363) Category II </li>
            </ul>
          </li>
          <li>V.A.4.e.&nbsp;&nbsp;&nbsp;Monitor trends in the incidence of target MDROs in the facility over time
            using appropriate statistical methods to determine whether MDRO rates
            are decreasing and whether additional interventions are needed.(<a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#154">154</a>,
            <a href="mdro_reference.html#183">183</a>, <a href="mdro_reference.html#193">193</a>, <a href="mdro_reference.html#205">205</a>, <a href="mdro_reference.html#209">209</a>, <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#242">242</a>,  <a href="mdro_reference.html#300">300</a>, <a href="mdro_reference.html#325">325</a>, <a href="mdro_reference.html#326">326</a>, <a href="mdro_reference.html#364">364</a>, <a href="mdro_reference.html#365">365</a>) Category IA
            <ul>
              <li>V.A.4.e.i.&nbsp;&nbsp;&nbsp;Specify isolate origin (i.e., location and clinical service) in MDRO
                monitoring protocols in hospitals and other large multi-unit facilities
                with high-risk patients.(<a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#152">152</a>-<a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#217">217</a>, 358, 361) Category IB </li>
              <li>V.A.4.e.ii.&nbsp;&nbsp;&nbsp;Establish a baseline (e.g., incidence) for targeted MDRO isolates by
                reviewing results of clinical cultures; if more timely or localized
                information is needed, perform baseline point prevalence studies of
                colonization in high-risk units. When possible, distinguish
                
                colonization from infection in analysis of these data.(<a href="mdro_reference.html#152">152</a>, 153, <a href="mdro_reference.html#183">183</a>,
                <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#189">189</a>, <a href="mdro_reference.html#190">190</a>, <a href="mdro_reference.html#193">193</a>, <a href="mdro_reference.html#205">205</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#365">365</a>) Category IB</li>
            </ul>
          </li>
        </ul>
      </li>
      <li>V.A.5.&nbsp;&nbsp;&nbsp;Infection control precautions to prevent transmission of MDROs
        <ul>
          <li>V.A.5.a.&nbsp;&nbsp;&nbsp;Follow Standard Precautions during all patient encounters in all settings in
            which healthcare is delivered.(119, <a href="mdro_reference.html#164">164</a>, 255, <a href="mdro_reference.html#315">315</a>, <a href="mdro_reference.html#316">316</a>) Category IB</li>
          <li>V.A.5.b.&nbsp;&nbsp;&nbsp;Use masks according to Standard Precautions when performing splashgenerating
            procedures (e.g., wound irrigation, oral suctioning, intubation);
            when caring for patients with open tracheostomies and the potential for
            projectile secretions; and in circumstances where there is evidence of
            transmission from heavily colonized sources (e.g., burn wounds). Masks
            are not otherwise recommended for prevention of MDRO transmission
            from patients to healthcare personnel during routine care (e.g., upon room
            entry).(<a href="mdro_reference.html#8">8</a>, 22, <a href="mdro_reference.html#151">151</a>, <a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#189">189</a>, <a href="mdro_reference.html#190">190</a>, <a href="mdro_reference.html#193">193</a>, <a href="mdro_reference.html#208">208</a>, <a href="mdro_reference.html#240">240</a>, <a href="mdro_reference.html#366">366</a>) Category IB </li>
          <li>V.A.5.c.&nbsp;&nbsp;&nbsp;Use of Contact Precautions
            V.A.5.c.i.&nbsp;&nbsp;&nbsp;In acute-care hospitals, implement Contact Precautions routinely for
            all patients infected with target MDROs and for patients that have
            been previously identified as being colonized with target MDROs
            (e.g., patients transferred from other units or facilities who are
            known to be colonized). (<a href="mdro_reference.html#11">11</a>, <a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#68">68</a>, <a href="mdro_reference.html#114">114</a>, <a href="mdro_reference.html#151">151</a>, <a href="mdro_reference.html#183">183</a>, <a href="mdro_reference.html#188">188</a>, <a href="mdro_reference.html#204">204</a>, <a href="mdro_reference.html#217">217</a>,
            <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#304">304</a>) Category IB
            <ul>
              <li>V.A.5.c.ii.&nbsp;&nbsp;&nbsp;In LTCFs, consider the individual patient's clinical situation and
                prevalence or incidence of MDRO in the facility when deciding
                whether to implement or modify Contact Precautions in addition to
                Standard Precautions for a patient infected or colonized with a
                target MDRO. Category II
                <ul>
                  <li>V.A.5.c.ii.1.&nbsp;&nbsp;&nbsp;For relatively healthy residents (e.g., mainly independent) follow
                    Standard Precautions, making sure that gloves and gowns are
                    used for contact with uncontrolled secretions, pressure ulcers,
                    draining wounds, stool incontinence, and ostomy tubes/bags. (78-
                    80, 85, <a href="mdro_reference.html#151">151</a>, <a href="mdro_reference.html#367">367</a>, 368) Category II </li>
                  <li>V.A.5.c.ii.2.&nbsp;&nbsp;&nbsp;For ill residents (e.g., those totally dependent upon healthcare
                    personnel for healthcare and activities of daily living, ventilatordependent)
                    and for those residents whose infected secretions or
                    drainage cannot be contained, use Contact Precautions in
                    addition to Standard Precautions.(<a href="mdro_reference.html#316">316</a>, 369, 370) Category II </li>
                </ul>
              </li>
              <li>V.A.5.c.iii.&nbsp;&nbsp;&nbsp;For MDRO colonized or infected patients without draining wounds,
                diarrhea, or uncontrolled secretions, establish ranges of permitted
                ambulation, socialization, and use of common areas based on their
                risk to other patients and on the ability of the colonized or infected
                patients to observe proper hand hygiene and other recommended
                precautions to contain secretions and excretions.(151, <a href="mdro_reference.html#163">163</a>, 371)
                Category II                </li>
            </ul>
          </li>
          <li>V.A.5.d.&nbsp;&nbsp;&nbsp;In ambulatory settings, use Standard Precautions for patients known to be
            infected or colonized with target MDROs, making sure that gloves and
            gowns are used for contact with uncontrolled secretions, pressure ulcers,
            draining wounds, stool incontinence, and ostomy tubes and bags. Category
            II </li>
          <li>V.A.5.e.&nbsp;&nbsp;&nbsp;In home care settings </li>
        </ul>
      </li>
    </ul>
  </li>
  <ul>
    <ul>
      <ul>
        <ul>
          <ul>
            <li>• Follow Standard Precautions making sure to use gowns and
              gloves for contact with uncontrolled secretions, pressure ulcers,
              draining wounds, stool incontinence, and ostomy tubes and
              bags. Category II </li>
            <li>• Limit the amount of reusable patient-care equipment that is
              brought into the home of patients infected or colonized with
              MDROs. When possible, leave patient-care equipment in the
              home until the patient is discharged from home care services.
              Category II </li>
            <li>• If noncritical patient-care equipment (e.g., stethoscopes) cannot
              remain in the home, clean and disinfect items before removing
              them from the home, using a low to intermediate level
              disinfectant, or place reusable items in a plastic bag for transport
              
              to another site for subsequent cleaning and disinfection.
              Category II </li>
          </ul>
        </ul>
              <li>V.A.5.e.i.&nbsp;&nbsp;&nbsp;No recommendation is made for routine use of gloves, gowns, or
                both to prevent MDRO transmission in ambulatory or home care
                settings. Unresolved issue </li>
        <li>V.A.5.e.ii.&nbsp;&nbsp;&nbsp;In hemodialysis units, follow the &quot;Recommendations to Prevent
          Transmission of Infections in Chronic Hemodialysis
          Patients&quot;(372)(www.cms.hhs.gov/home/regsguidance.asp).
          Category IC </li>
      </ul>
            <li>V.A.5.f.&nbsp;&nbsp;&nbsp;Discontinuation of Contact Precautions. No recommendation can be made
              regarding when to discontinue Contact Precautions. Unresolved issue (See
              Background for discussion of options) </li>
      <li>V.A.5.g.&nbsp;&nbsp;&nbsp;Patient placement in hospitals and LTCFs
        <ul>
          <li>V.A.5.g.i.&nbsp;&nbsp;&nbsp;When single-patient rooms are available, assign priority for these
            rooms to patients with known or suspected MDRO colonization or
            infection. Give highest priority to those patients who have conditions
            that may facilitate transmission, e.g., uncontained secretions or
            excretions.(<a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#110">110</a>, <a href="mdro_reference.html#151">151</a>, <a href="mdro_reference.html#188">188</a>, <a href="mdro_reference.html#208">208</a>, <a href="mdro_reference.html#240">240</a>, <a href="mdro_reference.html#304">304</a>) Category IB</li>
          <li> V.A.5.g.ii.&nbsp;&nbsp;&nbsp;When single-patient rooms are not available, cohort patients with
            the same MDRO in the same room or patient-care area.(<a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#38">38</a>, 92,
            151-153, 162, <a href="mdro_reference.html#183">183</a>, <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#188">188</a>, <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#304">304</a>) Category IB </li>
          <li>V.A.5.g.iii.&nbsp;&nbsp;&nbsp;When cohorting patients with the same MDRO is not possible, place
            MDRO patients in rooms with patients who are at low risk for
            acquisition of MDROs and associated adverse outcomes from
            infection and are likely to have short lengths of stay. Category II</li>
        </ul>
      </li>
    </ul>
    <li>V.A.6.&nbsp;&nbsp;&nbsp;Environmental measures      
      <ul>
        <li>V.A.6.a.&nbsp;&nbsp;&nbsp;Clean and disinfect surfaces and equipment that may be contaminated with
          pathogens, including those that are in close proximity to the patient (e.g.,
          bed rails, over bed tables) and frequently-touched surfaces in the patient
          care environment (e.g., door knobs, surfaces in and surrounding toilets in
          patients' rooms) on a more frequent schedule compared to that for minimal
          
          touch surfaces (e.g., horizontal surfaces in waiting rooms).(111, <a href="mdro_reference.html#297">297</a>, 373)
          Category IB          </li>
        <li>V.A.6.b.&nbsp;&nbsp;&nbsp;Dedicate noncritical medical items to use on individual patients known to
          be infected or colonized with MDROs.(<a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#323">323</a>, 374, 375) Category
          IB          </li>
        <li>V.A.6.c.&nbsp;&nbsp;&nbsp;Prioritize room cleaning of patients on Contact Precautions. Focus on
          cleaning and disinfecting frequently touched surfaces (e.g., bedrails,
          bedside commodes, bathroom fixtures in the patient's room, doorknobs)
          and equipment in the immediate vicinity of the patient.(109, <a href="mdro_reference.html#110">110</a>, 114-117,
          <a href="mdro_reference.html#297">297</a>, <a href="mdro_reference.html#301">301</a>, 373, 376, 377) Category IB</li>
      </ul>
    </li>
  </ul>
  <li>V.B.&nbsp;&nbsp;&nbsp;Intensified interventions to prevent MDRO transmission
The interventions presented below have been utilized in various combinations to
reduce transmission of MDROs in healthcare facilities. Neither the effectiveness of
individual components nor that of specific combinations of control measures has
been assessed in controlled trials. Nevertheless, various combinations of control
elements selected under the guidance of knowledgeable content experts have
repeatedly reduced MDRO transmission rates in a variety of healthcare settings.
    <ul>
      <li>V.B.1.&nbsp;&nbsp;&nbsp;Indications and approach        
        <ul>
          <li>V.B.1.a.&nbsp;&nbsp;&nbsp;Indications for intensified MDRO control efforts (VII.B.1.a.i and VII.B.1.a.ii)
            should result in selection and implementation of one or more of the
            interventions described in VII.B.2 to VII.B.8 below. Individualize the
            selection of control measures according to local considerations(<a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#11">11</a>, <a href="mdro_reference.html#38">38</a>,
            68, <a href="mdro_reference.html#114">114</a>, <a href="mdro_reference.html#152">152</a>-<a href="mdro_reference.html#154">154</a>, 183-185, <a href="mdro_reference.html#189">189</a>, <a href="mdro_reference.html#190">190</a>, <a href="mdro_reference.html#193">193</a>, <a href="mdro_reference.html#194">194</a>, <a href="mdro_reference.html#209">209</a>, <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#312">312</a>, <a href="mdro_reference.html#364">364</a>,
            <a href="mdro_reference.html#365">365</a>). Category IB 
            <ul>
              <li>V.B.1.a.i.&nbsp;&nbsp;&nbsp;When incidence or prevalence of MDROs are not decreasing
                despite implementation of and correct adherence to the routine
                control measures described above, intensify MDRO control efforts
                by adopting one or more of the interventions described below.(92,
                <a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#183">183</a>, <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#193">193</a>, <a href="mdro_reference.html#365">365</a>) Category IB                </li>
              <li>V.B.1.a.ii.&nbsp;&nbsp;&nbsp;When the first case or outbreak of an epidemiologically important
                MDRO (e.g., VRE, MRSA, VISA, VRSA, MDR-GNB) is identified
                
                within a healthcare facility or unit.(22, 23, 25, <a href="mdro_reference.html#68">68</a>, <a href="mdro_reference.html#170">170</a>, <a href="mdro_reference.html#172">172</a>, <a href="mdro_reference.html#184">184</a>,
                <a href="mdro_reference.html#240">240</a>, <a href="mdro_reference.html#242">242</a>, 378) Category IB                </li>
            </ul>
          </li>
          <li>V.B.1.b.&nbsp;&nbsp;&nbsp;Continue to monitor the incidence of target MDRO infection and
                colonization after additional interventions are implemented. If rates do not
                decrease, implement more interventions as needed to reduce MDRO
                transmission.(<a href="mdro_reference.html#11">11</a>, <a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#68">68</a>, 92, <a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#175">175</a>, <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#365">365</a>) Category IB                </li>
        </ul>
      </li>
      <li>V.B.2.&nbsp;&nbsp;&nbsp;Administrative measures                
        <ul>
          <li>V.B.2.a.&nbsp;&nbsp;&nbsp;Identify persons with experience in infection control and the epidemiology
            of MDRO, either in house or through outside consultation, for assessment
            of the local MDRO problem and for the design, implementation, and
            evaluation of appropriate control measures (<a href="mdro_reference.html#3">3</a>, <a href="mdro_reference.html#68">68</a>, <a href="mdro_reference.html#146">146</a>, 151-<a href="mdro_reference.html#154">154</a>, 167, <a href="mdro_reference.html#184">184</a>,
            <a href="mdro_reference.html#190">190</a>, <a href="mdro_reference.html#193">193</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#328">328</a>, 377). Category IB            </li>
          <li>V.B.2.b.&nbsp;&nbsp;&nbsp;Provide necessary leadership, funding, and day-to-day oversight to
            implement interventions selected. Involve the governing body and
            leadership of the healthcare facility or system that have organizational
            responsibility for this and other infection control efforts.(<a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#154">154</a>,
            <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#189">189</a>, <a href="mdro_reference.html#190">190</a>, 208) Category IB            </li>
          <li>V.B.2.c.&nbsp;&nbsp;&nbsp;Evaluate healthcare system factors for their role in creating or perpetuating
            transmission of MDROs, including: staffing levels, education and training,
            availability of consumable and durable resources, communication
            processes, policies and procedures, and adherence to recommended
            infection control measures (e.g., hand hygiene and Standard or Contact
            Precautions). Develop, implement, and monitor action plans to correct
            system failures.(<a href="mdro_reference.html#3">3</a>, <a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#172">172</a>, <a href="mdro_reference.html#173">173</a>, <a href="mdro_reference.html#175">175</a>, <a href="mdro_reference.html#188">188</a>, <a href="mdro_reference.html#196">196</a>, <a href="mdro_reference.html#198">198</a>, <a href="mdro_reference.html#199">199</a>, <a href="mdro_reference.html#208">208</a>,
            <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#280">280</a>, <a href="mdro_reference.html#323">323</a>, <a href="mdro_reference.html#379">379</a>, <a href="mdro_reference.html#380">380</a>) Category IB            </li>
          <li>V.B.2.d.&nbsp;&nbsp;&nbsp;During the process, update healthcare providers and administrators on the
            progress and effectiveness of the intensified interventions. Include
            information on changes in prevalence, rates of infection and colonization;
            results of assessments and corrective actions for system failures; degrees
            of adherence to recommended practices; and action plans to improve
            
            adherence to recommended infection control practices to prevent MDRO
            transmission.(<a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#159">159</a>, <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#204">204</a>, <a href="mdro_reference.html#205">205</a>, <a href="mdro_reference.html#312">312</a>, <a href="mdro_reference.html#332">332</a>, 381) Category IB            </li>
        </ul>
      </li>
      <li>V.B.3.&nbsp;&nbsp;&nbsp;Educational interventions
            Intensify the frequency of MDRO educational programs for healthcare
            personnel, especially those who work in areas in which MDRO rates are not
            decreasing. Provide individual or unit-specific feedback when available.(<a href="mdro_reference.html#3">3</a>, <a href="mdro_reference.html#38">38</a>,
            <a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#159">159</a>, <a href="mdro_reference.html#170">170</a>, <a href="mdro_reference.html#182">182</a>, <a href="mdro_reference.html#183">183</a>, <a href="mdro_reference.html#189">189</a>, <a href="mdro_reference.html#190">190</a>, <a href="mdro_reference.html#193">193</a>, <a href="mdro_reference.html#194">194</a>, <a href="mdro_reference.html#204">204</a>, <a href="mdro_reference.html#205">205</a>, <a href="mdro_reference.html#209">209</a>, <a href="mdro_reference.html#215">215</a>, <a href="mdro_reference.html#218">218</a>,
            <a href="mdro_reference.html#312">312</a>) Category IB            </li>
      <li>V.B.4.&nbsp;&nbsp;&nbsp;Judicious use of antimicrobial agents
            Review the role of antimicrobial use in perpetuating the MDRO problem
            targeted for intensified intervention. Control and improve antimicrobial use as
            indicated. Antimicrobial agents that may be targeted include vancomycin,
            third-generation cephalosporins, and anti-anaerobic agents for VRE(217);
            third-generation cephalosporins for ESBLs(212, <a href="mdro_reference.html#214">214</a>, 215); and quinolones
            and carbapenems(80, <a href="mdro_reference.html#156">156</a>, <a href="mdro_reference.html#166">166</a>, <a href="mdro_reference.html#174">174</a>, <a href="mdro_reference.html#175">175</a>, <a href="mdro_reference.html#209">209</a>, <a href="mdro_reference.html#218">218</a>, <a href="mdro_reference.html#242">242</a>, 254, <a href="mdro_reference.html#329">329</a>, 334, 335,
            337, 341). Category IB            </li>
      <li>V.B.5.&nbsp;&nbsp;&nbsp;Surveillance            
        <ul>
          <li>V.B.5.a.&nbsp;&nbsp;&nbsp;Calculate and analyze prevalence and incidence rates of targeted MDRO
            infection and colonization in populations at risk; when possible, distinguish
            colonization from infection(<a href="mdro_reference.html#152">152</a>, 153, <a href="mdro_reference.html#183">183</a>, <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#189">189</a>, <a href="mdro_reference.html#190">190</a>, <a href="mdro_reference.html#193">193</a>, <a href="mdro_reference.html#205">205</a>, <a href="mdro_reference.html#215">215</a>,
            <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#365">365</a>). Category IB            
            <ul>
              <li>V.B.5.a.i.&nbsp;&nbsp;&nbsp;Include only one isolate per patient, not multiple isolates from the
                same patient, when calculating rates(347, 382). Category II                </li>
              <li>V.B.5.a.ii.&nbsp;&nbsp;&nbsp;Increase the frequency of compiling and monitoring antimicrobial
                susceptibility summary reports for a targeted MDRO as indicated by
                an increase in incidence of infection or colonization with that MDRO.
                Category II                </li>
            </ul>
          </li>
          <li>V.B.5.b.&nbsp;&nbsp;&nbsp;Develop and implement protocols to obtain active surveillance cultures
                (ASC) for targeted MDROs from patients in populations at risk (e.g.,
                patients in intensive care, burn, bone marrow/stem cell transplant, and
                oncology units; patients transferred from facilities known to have high
                
                MDRO prevalence rates; roommates of colonized or infected persons; and
                patients known to have been previously infected or colonized with an
                MDRO).(<a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#68">68</a>, <a href="mdro_reference.html#114">114</a>, 151-154, 167, <a href="mdro_reference.html#168">168</a>, <a href="mdro_reference.html#183">183</a>, <a href="mdro_reference.html#184">184</a>, 187-190, <a href="mdro_reference.html#192">192</a>, <a href="mdro_reference.html#193">193</a>,
                <a href="mdro_reference.html#217">217</a>, 242) Category IB                
            <ul>
              <li>V.B.5.b.i.&nbsp;&nbsp;&nbsp;Obtain ASC from areas of skin breakdown and draining wounds. In
                addition, include the following sites according to target MDROs:                
                <ul>
                  <li>V.B.5.b.i.1.&nbsp;&nbsp;&nbsp;For MRSA: Sampling the anterior nares is usually sufficient;
                    throat, endotracheal tube aspirate, percutaneous gastrostomy
                    sites, and perirectal or perineal cultures may be added to increase
                    the yield. Swabs from several sites may be placed in the same
                    selective broth tube prior to transport.(117, 383, 384) Category IB                    </li>
                  <li>V.B.5.b.i.2.&nbsp;&nbsp;&nbsp;For VRE: Stool, rectal, or perirectal samples should be
                    collected.(154, <a href="mdro_reference.html#193">193</a>, <a href="mdro_reference.html#217">217</a>, 242)
                    Category IB                    </li>
                  <li>V.B.5.b.i.3.&nbsp;&nbsp;&nbsp;For MDR-GNB: Endotracheal tube aspirates or sputum should
                    be cultured if a respiratory tract reservoir is suspected, (e.g.,
                    Acinetobacter spp., Burkholderia spp.).(385, 386) Category IB.                    </li>
                </ul>
              </li>
              <li>V.B.5.b.ii.&nbsp;&nbsp;&nbsp;Obtain surveillance cultures for the target MDRO from patients at
                    the time of admission to high-risk areas, e.g., ICUs, and at periodic
                    intervals as needed to assess MDRO transmission.(<a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#151">151</a>, <a href="mdro_reference.html#154">154</a>,
                    <a href="mdro_reference.html#159">159</a>, <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#208">208</a>, <a href="mdro_reference.html#215">215</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#387">387</a>) Category IB                    </li>
            </ul>
          </li>
          <li>V.B.5.c.&nbsp;&nbsp;&nbsp;Conduct culture surveys to assess the efficacy of the enhanced MDRO
                    control interventions.                    
            <ul>
              <li>V.B.5.c.i.&nbsp;&nbsp;&nbsp;Conduct serial (e.g., weekly, until transmission has ceased and then
                decreasing frequency) unit-specific point prevalence culture surveys
                of the target MDRO to determine if transmission has decreased or
                ceased.(107, 167, <a href="mdro_reference.html#175">175</a>, <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#188">188</a>, <a href="mdro_reference.html#218">218</a>, <a href="mdro_reference.html#339">339</a>) Category IB                </li>
              <li>V.B.5.c.ii.&nbsp;&nbsp;&nbsp;Repeat point-prevalence culture surveys at routine intervals or at
                time of patient discharge or transfer until transmission has
                ceased.(<a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#152">152-154</a>, <a href="mdro_reference.html#168">168</a>, <a href="mdro_reference.html#178">178</a>, <a href="mdro_reference.html#190">190</a>, <a href="mdro_reference.html#215">215</a>, <a href="mdro_reference.html#218">218</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#388">388</a>) Category IB                </li>
              <li>V.B.5.c.iii.&nbsp;&nbsp;&nbsp;If indicated by assessment of the MDRO problem, collect cultures to
                asses the colonization status of roommates and other patients with
                substantial exposure to patients with known MDRO infection or
                colonization.(25, <a href="mdro_reference.html#68">68</a>, 167, 193) Category IB                </li>
            </ul>
          </li>
          <li>V.B.5.d.&nbsp;&nbsp;&nbsp;Obtain cultures of healthcare personnel for target MDRO when there is
                epidemiologic evidence implicating the healthcare staff member as a
                source of ongoing transmission.(153, <a href="mdro_reference.html#365">365</a>) Category IB                </li>
        </ul>
      </li>
      <li>V.B.6.&nbsp;&nbsp;&nbsp;Enhanced infection control precautions                
        <ul>
          <li>V.B.6.a.&nbsp;&nbsp;&nbsp;Use of Contact Precautions            
            <ul>
              <li>V.B.6.a.i.&nbsp;&nbsp;&nbsp;Implement Contact Precautions routinely for all patients colonized or
                infected with a target MDRO.(<a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#11">11</a>, <a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#68">68</a>, <a href="mdro_reference.html#114">114</a>, <a href="mdro_reference.html#151">151</a>, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#183">183</a>, <a href="mdro_reference.html#188">188</a>,
                <a href="mdro_reference.html#189">189</a>, <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#304">304</a>) Category IA                </li>
              <li>V.B.6.a.ii.&nbsp;&nbsp;&nbsp;Because environmental surfaces and medical equipment, especially
                those in close proximity to the patient, may be contaminated, don
                gowns and gloves before or upon entry to the patient's room or
                cubicle.(<a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#68">68</a>, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#187">187</a>, <a href="mdro_reference.html#189">189</a>, 242) Category IB                </li>
              <li>V.B.6.a.iii.&nbsp;&nbsp;&nbsp;In LTCFs, modify Contact Precautions to allow MDROcolonized/
                infected patients whose site of colonization or infection
                can be appropriately contained and who can observe good hand
                hygiene practices to enter common areas and participate in group
                activities.(78, 86, <a href="mdro_reference.html#151">151</a>, <a href="mdro_reference.html#367">367</a>) Category IB                </li>
            </ul>
          </li>
          <li>V.B.6.b.&nbsp;&nbsp;&nbsp;When ASC are obtained as part of an intensified MDRO control program,
            implement Contact Precautions until the surveillance culture is reported
            negative for the target MDRO.(<a href="mdro_reference.html#8">8</a>, 30, 153, <a href="mdro_reference.html#389">389</a>, 390) Category IB            </li>
          <li>V.B.6.c.&nbsp;&nbsp;&nbsp;No recommendation is made regarding universal use of gloves, gowns, or
            both in high-risk units in acute-care hospitals.(153, <a href="mdro_reference.html#273">273</a>, <a href="mdro_reference.html#312">312</a>,  <a href="mdro_reference.html#320">320</a>, 391)
            Unresolved issue            </li>
        </ul>
      </li>
      <li>V.B.7.&nbsp;&nbsp;&nbsp;Implement policies for patient admission and placement as needed to prevent
        transmission of a problem MDRO.(183, <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#189">189</a>, <a href="mdro_reference.html#193">193</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#339">339</a>, 392)
        Category IB        
        <ul>
          <ul>
            <li>V.B.7.a.i.&nbsp;&nbsp;&nbsp;Place MDRO patients in single-patient rooms.(<a href="mdro_reference.html#6">6</a>, <a href="mdro_reference.html#151">151</a>, <a href="mdro_reference.html#158">158</a>, <a href="mdro_reference.html#160">160</a>, <a href="mdro_reference.html#166">166</a>,
              <a href="mdro_reference.html#170">170</a>, <a href="mdro_reference.html#187">187</a>, <a href="mdro_reference.html#208">208</a>, <a href="mdro_reference.html#240">240</a>, <a href="mdro_reference.html#282">282</a>, 393-395) Category IB
              V.B.7.a.ii.&nbsp;&nbsp;&nbsp;Cohort patients with the same MDRO in designated areas (e.g.,
              rooms, bays, patient care areas.(<a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#151">151</a>, <a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#159">159</a>, <a href="mdro_reference.html#161">161</a>, <a href="mdro_reference.html#176">176</a>, <a href="mdro_reference.html#181">181</a>,
              <a href="mdro_reference.html#183">183</a>, <a href="mdro_reference.html#184">184</a>, <a href="mdro_reference.html#188">188</a>, <a href="mdro_reference.html#208">208</a>, <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#280">280</a>, <a href="mdro_reference.html#339">339</a>, 344) Category IB              </li>
            <li>V.B.7.a.iii.&nbsp;&nbsp;&nbsp;When transmission continues despite adherence to Standard and
              Contact Precautions and cohorting patients, assign dedicated
              nursing and ancillary service staff to the care of MDRO patients
              only. Some facilities may consider this option when intensified
              measures are first implemented.(184, <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#242">242</a>, <a href="mdro_reference.html#278">278</a>) Category IB</li>
            <li> V.B.7.a.iv.&nbsp;&nbsp;&nbsp;Stop new admissions to the unit of facility if transmission continues
              despite the implementation of the enhanced control measures
              described above. (Refer to state or local regulations that may apply
              upon closure of hospital units or services.).(<a href="mdro_reference.html#9">9</a>, <a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#146">146</a>, <a href="mdro_reference.html#159">159</a>, <a href="mdro_reference.html#161">161</a>,
              <a href="mdro_reference.html#168">168</a>, <a href="mdro_reference.html#175">175</a>, <a href="mdro_reference.html#205">205</a>, <a href="mdro_reference.html#279">279</a>, <a href="mdro_reference.html#280">280</a>, <a href="mdro_reference.html#332">332</a>, <a href="mdro_reference.html#339">339</a>, 396) Category IB              </li>
          </ul>
        </ul>
      </li>
      <li>V.B.8.&nbsp;&nbsp;&nbsp;Enhanced environmental measures        
        <ul>
          <li>V.B.8.a.&nbsp;&nbsp;&nbsp;Implement patient-dedicated or single-use disposable noncritical
            equipment (e.g., blood pressure cuff, stethoscope) and instruments and
            devices.(<a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#104">104</a>, <a href="mdro_reference.html#151">151</a>, <a href="mdro_reference.html#156">156</a>, <a href="mdro_reference.html#159">159</a>, <a href="mdro_reference.html#163">163</a>, <a href="mdro_reference.html#181">181</a>, <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#323">323</a>, <a href="mdro_reference.html#329">329</a>, <a href="mdro_reference.html#367">367</a>, <a href="mdro_reference.html#389">389</a>, <a href="mdro_reference.html#390">390</a>,
            <a href="mdro_reference.html#394">394</a>) Category IB            </li>
          <li>V.B.8.b.&nbsp;&nbsp;&nbsp;Intensify and reinforce training of environmental staff who work in areas
            targeted for intensified MDRO control and monitor adherence to
            environmental cleaning policies. Some facilities may choose to assign
            dedicated staff to targeted patient care areas to enhance consistency of
            proper environmental cleaning and disinfection services.(<a href="mdro_reference.html#38">38</a>, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#159">159</a>, <a href="mdro_reference.html#165">165</a>,
            <a href="mdro_reference.html#172">172</a>, <a href="mdro_reference.html#173">173</a>, <a href="mdro_reference.html#175">175</a>, <a href="mdro_reference.html#178">178-181</a>, <a href="mdro_reference.html#193">193</a>, <a href="mdro_reference.html#205">205</a>, <a href="mdro_reference.html#208">208</a>, <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#279">279</a>, <a href="mdro_reference.html#301">301</a>, <a href="mdro_reference.html#327">327</a>, <a href="mdro_reference.html#339">339</a>, 397)
            Category IB</li>
          <li> V.B.8.c.&nbsp;&nbsp;&nbsp;Monitor (i.e., supervise and inspect) cleaning performance to ensure
            consistent cleaning and disinfection of surfaces in close proximity to the
            patient and those likely to be touched by the patient and HCP (e.g.,
            
            bedrails, carts, bedside commodes, doorknobs, faucet handles).(<a href="mdro_reference.html#8">8</a>, <a href="mdro_reference.html#38">38</a>,
            <a href="mdro_reference.html#109">109</a>, <a href="mdro_reference.html#111">111</a>, <a href="mdro_reference.html#154">154</a>, <a href="mdro_reference.html#169">169</a>, <a href="mdro_reference.html#180">180</a>, <a href="mdro_reference.html#208">208</a>, <a href="mdro_reference.html#217">217</a>, <a href="mdro_reference.html#301">301</a>, <a href="mdro_reference.html#333">333</a>, <a href="mdro_reference.html#398">398</a>) Category IB            </li>
          <li>V.B.8.d.&nbsp;&nbsp;&nbsp;Obtain environmental cultures (e.g., surfaces, shared medical equipment)
            when there is epidemiologic evidence that an environmental source is
            associated with ongoing transmission of the targeted MDRO.(<a href="mdro_reference.html#399">399</a>-<a href="mdro_reference.html#402">402</a>)
            Category IB            </li>
          <li>V.B.8.e.&nbsp;&nbsp;&nbsp;Vacate units for environmental assessment and intensive cleaning when
            previous efforts to eliminate environmental reservoirs have failed.(<a href="mdro_reference.html#175">175</a>,
            <a href="mdro_reference.html#205">205</a>, <a href="mdro_reference.html#279">279</a>, <a href="mdro_reference.html#339">339</a>, <a href="mdro_reference.html#403">403</a>) Category II            </li>
        </ul>
      </li>
      <li>V.B.9.&nbsp;&nbsp;&nbsp;Decolonization        
        <ul>
          <li>V.B.9.a.&nbsp;&nbsp;&nbsp;Consult with physicians with expertise in infectious diseases and/or
            healthcare epidemiology on a case-by-case basis regarding the
            appropriate use of decolonization therapy for patients or staff during limited
            periods of time, as a component of an intensified MRSA control program
            ).(<a href="mdro_reference.html#152">152</a>, <a href="mdro_reference.html#168">168</a>, <a href="mdro_reference.html#170">170</a>, <a href="mdro_reference.html#172">172</a>, <a href="mdro_reference.html#183">183</a>, <a href="mdro_reference.html#194">194</a>, <a href="mdro_reference.html#304">304</a>) Category II            </li>
          <li>V.B.9.b.&nbsp;&nbsp;&nbsp;When decolonization for MRSA is used, perform susceptibility testing for
            the decolonizing agent against the target organism in the individual being
            treated or the MDRO strain that is epidemiologically implicated in
            transmission. Monitor susceptibility to detect emergence of resistance to
            the decolonizing agent. Consult with a microbiologist for appropriate testing
            for mupirocin resistance, since standards have not been established.(<a href="mdro_reference.html#289">289</a>,
            <a href="mdro_reference.html#290">290</a>, <a href="mdro_reference.html#304">304</a>, <a href="mdro_reference.html#308">308</a>) Category IB
            <ul>
              <li>V.B.9.b.i.&nbsp;&nbsp;&nbsp;Because mupirocin-resistant strains may emerge and because it is
                unusual to eradicate MRSA when multiple body sites are colonized,
                do not use topical mupirocin routinely for MRSA decolonization of
                patients as a component of MRSA control programs in any
                healthcare setting.(<a href="mdro_reference.html#289">289</a>, <a href="mdro_reference.html#404">404</a>) Category IB                </li>
              <li>V.B.9.b.ii.&nbsp;&nbsp;&nbsp;Limit decolonization of HCP found to be colonized with MRSA to
                persons who have been epidemiologically linked as a likely source
                of ongoing transmission to patients. Consider reassignment of HCP
                
                if decolonization is not successful and ongoing transmission to
                patients persists.(120, <a href="mdro_reference.html#122">122</a>, 168) Category IB                </li>
            </ul>
          </li>
          <li>V.B.9.c.&nbsp;&nbsp;&nbsp;No recommendation can be made for decolonizing patients with VRE or
                MDR-GNB. Regimens and efficacy of decolonization protocols for VRE and
                MDR-GNB have not been established.(<a href="mdro_reference.html#284">284</a>, <a href="mdro_reference.html#286">286</a>, <a href="mdro_reference.html#288">288</a>, <a href="mdro_reference.html#307">307</a>, <a href="mdro_reference.html#387">387</a>, <a href="mdro_reference.html#405">405</a>)
                Unresolved issue</li>
        </ul>
      </li>
    </ul>
  </li>
</ul>
<p>&nbsp;</p>

<div class="margin">
<p>&nbsp;</p>
</div>

<!-- InstanceEndEditable -->
				  <!-- InstanceBeginEditable name="content-main" -->
                  
 
                  
                  
                    <p><div id="breadBox">
	<ul id="breadcrumbs">
		<li style="display:none;"></li>
	</ul>
</div>
				  <div class="module rounders grey multiPage-horiz" id="tableOfContent">
                    <div class="inner">
                      <div class="t"></div>
                      <div class="hd">
                        <h4><span><a href="mdro_3.html">Previous Page</a></span> <span class="nextLink"><a href="mdro_glossary.html">Next Page</a></span> </h4>
                      </div>
                      <div class="bd"><span><a href="mdro_toc.html">Table of Contents</a></span></div>
                    </div>
				    <div class="b">
                      <div></div>
			        </div>
				    </div>
                    </p>
                 
                  
                 
                  <!-- InstanceEndEditable -->
					<!-- /end .main-inner --></div>
					
					<div id="linkPolicy">&nbsp;</div>
				<!-- /end #content-main--></div>
				
			<!-- /end #content-inner --></div>
			
			<!-- ########## RIGHT COLUMN STARTS HERE ########## -->
			<div id="content-secondary">
				<div class="pageOptions">
					<div class="pageOptions-inner">
						<ul id="services" class="services">
							<li class="print"><a href="javascript:window.print();" title="Print page.">Print page</a></li>
						</ul>
						<!-- InstanceBeginEditable name="local-options" -->
                   <ul>
                    <h5>Download page:</h5>
								<li class="pdf"><a href="https://www.cdc.gov/hicpac/pdf/MDRO/Pages28_33MDROGuideline2006.pdf">PDF [24 KB]</a></li>
                    </ul>
					<!--<ul>
						
					</ul>-->
					<!-- InstanceEndEditable --><!-- InstanceBeginEditable name="languages" -->				<!-- InstanceEndEditable -->
					</div>
				</div>
				
				
				<!-- InstanceBeginEditable name="gov-delivery" -->
			  
			<!-- InstanceEndEditable -->
				<!-- InstanceBeginEditable name="contact-info" -->
			<div id="contact-info">
	<h5>Contact Us:</h5>
	<ul class="noBullet">
		<li class="mail">Centers for Disease Control and Prevention<br />
		1600 Clifton Rd<br />
		Atlanta, GA 30333</li>
		<li class="phone">800-CDC-INFO<br />
		(800-232-4636)<br />
		TTY: (888) 232-6348</li>
		<li><a href="../../cdc-info/requestform.html">Contact CDC&ndash;INFO</a></li>
	</ul>
</div>
			<!-- InstanceEndEditable -->
			<!-- /end #content-secondary --></div>
			
			<!-- ########## LEFT NAVIGATION STARTS HERE ########## -->
			<div id="nav-container"><!-- InstanceBeginEditable name="left-nav-include" -->
			  <div id="nav">
  <h3><a href="../index.html">HICPAC</a></h3>
	<ul id="nav-primary">
    <li><a href="../about.html">About HICPAC</a></li>
    <li><a href="../roster.html">Member Roster</a></li>
    <li><a href="../charter.html">Charter</a> </li>
    <li><a href="../eCalendar.html">Event Calendar</a>
      <!--ul>
        <li><a href="/hicpac/agenda.html">Meeting Agenda</a></li>  
      </ul-->
    </li>
    <li><a href="../guidelineMethod/guidelineMethod.html">Methodology Guideline</a>
      <ul>
        <li><a href="../guidelineMethod/001_methods_background.html">Background</a></li>
        <li><a href="../guidelineMethod/002_methods_emergingNeeds.html">Strengthening HICPAC Guidelines to Address Emerging Needs</a></li>
        <li><a href="../guidelineMethod/003_methods_Organiz2AccomplishGoals.html">Organizing to Accomplish Our Goals</a> </li>
        <li><a href="../guidelineMethod/004_methods_guidelineDevelopment.html">Methods in Guideline Development</a></li>
        <li><a href="../guidelineMethod/005_methods_challengesOpportunities.html">Looking to Future Challenges and Opportunities</a></li>
        <li><a href="../guidelineMethod/007_methods_References.html">References</a></li>
        <li><a href="../guidelineMethod/008_methods_tables.html">Tables</a></li>
        <li><a href="../guidelineMethod/011_methods_figures.html">Figures</a></li>
      </ul>
    </li>
	<!--li><a href="/hicpac/projects_in_progress.html">Projects in Progress</a></li-->
	<li><a href="../pubs.html">Publications</a>
			<ul>
			  <li><a href="../BSI/BSI-guidelines-2011.html">2011 Guidelines for the Prevention of Intravascular Catheter-Related Infections</a>
		        <ul>
		          <li><a href="../BSI/toc-BSI-guidelines-2011.html">Table of Contents</a></li>
		          <li><a href="../BSI/01-BSI-guidelines-2011.html">Notice to Readers</a> </li>
		          <li><a href="../BSI/02-bsi-summary-of-recommendations-2011.html">Summary Of Recommendations</a> </li>
		          <li><a href="../BSI/03-bsi-summary-of-recommendations-2011.html">Patient Cleansing 
		            </a></li>
		          <li><a href="../BSI/04-bsi-background-info-2011.html">Background Information</a></li>
		          <li><a href="../BSI/05-bsi-background-info-2011.html">Maximal Sterile Barrier Precautions 
		            </a></li>
		          <li><a href="../BSI/06-bsi-background-info-2011.html">Antibiotic Lock Prophylaxis, Antimicrobial Catheter Flush and Catheter Lock Prophylaxis 
		            </a></li>
		          <li><a href="../BSI/07-bsi-background-info-2011.htmles-2011.html">Replacement of Administration Sets</a></li>
		          <li><a href="../BSI/bsi-table-1-2011.html">Table 1. Catheters used for venous and arterial access</a></li>
		          <li><a href="../BSI/13-references-BSI-guidelines-2011.html">References</a></li>
		          <li><a href="../BSI/11-appendix-B-BSI-guidelines-2011.html">Appendix B. Disclosure of financial interests or relationships</a></li>
		          <li><a href="../BSI/12-appendix-C-BSI-guidelines-2011.html">Appendix C. Summary of Recommendations</a></li>
	            </ul>
			  </li>
		      <li><a href="../norovirus/002_norovirus-toc.html">2011 Norovirus Guidelines
		        </a>
		        <ul>
		          <li><a href="../norovirus/003_norovirus-abbreviations.html">Abbreviations</a></li>
					   
					   <li><a href="../norovirus/001_norovirus.html">Acknowledgement</a></li>
					   <li><a href="../norovirus/004_norovirus-exec-summary.html">Executive Summary</a></li>
					   <li><a href="../norovirus/005_norovirus-summaryOrecs.html">Summary of Recommendations</a></li>
					   <li><a href="../norovirus/006_norovirus-implement-audit.html">Implementation and Audit</a> </li>
					   <li> <a href="../norovirus/007_norovirus-recs-further-research.html">Recommendations for Further Research					     </a></li>
					   <li><a href="../norovirus/008_norovirus-background.html">Background					     </a></li>
					   <li><a href="../norovirus/009_norovirus-scope.html">Scope and Purpose</a> </li>
					   <li><a href="../norovirus/010_norovirus-methods.html">Methods</a> </li>
					   <li><a href="../norovirus/011_norovirus-evidence-review.html">Evidence Review Question 1</a>				       </li>
                       <li><a href="../norovirus/012_norovirus-evidence-q2.html">Question 2</a></li>
                       <li><a href="../norovirus/013_norovirus-evidence-q3.html">Question 3</a></li>
                  <li><a href="../norovirus/norovirus-appendix-1.html">Appendix 1</a></li>
                       <li><a href="../norovirus/norovirus-appendix-1b.html">Appendix 1B</a> </li>
                       <li><a href="../norovirus/tables/evidence-Table1.html">Evidence, Grade &amp; Study Quality Assessment Tables</a></li>
                  <li><a href="../norovirus/norovirus-appendix-3.html">Appendix 3</a></li>
                       <li><a href="../norovirus/norovirus-appendix-4.html">Appendix 4</a></li>
                       <li><a href="../norovirus/norovirus-references.html">References</a></li>
		        </ul>
		      </li>
	          <li><a href="../Disinfection_Sterilization/acknowledg.html">2008 Disinfection &amp; Sterilization Guideline</a>               
	            <ul>
	              <li><a href="../Disinfection_Sterilization/toc.html">Table of Contents</a></li>
	              <li><a href="../Disinfection_Sterilization/1_sumIntroMethTerms.html">Executive Summary</a> </li>
	              <li><a href="../Disinfection_Sterilization/2_approach.html">Approach to Disinfection and Sterilization</a> 
	                  <ul>
	                    <li><a href="../Disinfection_Sterilization/3_0disinfectEquipment.html">Disinfection of Healthcare Equipment</a></li>
                        <li><a href="../Disinfection_Sterilization/3_1deLaparoArthro.html">Laparoscopes and Arthroscopes</a> </li>
                        <li><a href="../Disinfection_Sterilization/3_2contaminatedDevices.html">Disinfection of HBV, HCV, HIV or TB-Contaminated Devices</a></li>
                        <li><a href="../Disinfection_Sterilization/3_3inactivBioAgents.html">Inactivation of Bioterrorist Agents</a></li>
                        <li><a href="../Disinfection_Sterilization/3_4surfaceDisinfection.html">Surface Disinfection</a></li>
                    </ul>
	              </li>
                  <li><a href="../Disinfection_Sterilization/4_0efficacyDS.html">Factors Affecting The Efficacy Of Disinfection And Sterilization</a></li>
                  <li><a href="../Disinfection_Sterilization/5_0cleaning.html">Cleaning</a></li>
                  <li><a href="../Disinfection_Sterilization/6_0disinfection.html">Disinfection</a>
                    <ul>
                      <li><a href="../Disinfection_Sterilization/7_0formaldehyde.html">Formaldehyde</a></li>
                      <li><a href="../Disinfection_Sterilization/8_0Iodophors.html">Iodophors</a></li>
                      <li><a href="../Disinfection_Sterilization/9_0PceticAcidHydroPoxide.html">Peracetic Acid and Hydrogen Peroxide</a></li>
                    </ul>
                  </li>
                  <li><a href="../Disinfection_Sterilization/10_0MiscAgents.html">Miscellaneous Inactivating Agents</a></li>
                  <li><a href="../Disinfection_Sterilization/11_0regulatory_Framework.html">Regulatory Framework for Disinfectants and Sterilants</a></li>
                  <li><a href="../Disinfection_Sterilization/13_0Sterilization.html">Sterilization</a>
                      <ul>
	                      
                        <li><a href="../Disinfection_Sterilization/13_02sterilization.html">Low-Temperature Sterilization Technologies</a></li>
		                          
                        <li><a href="../Disinfection_Sterilization/13_06PeraceticAcidSterilization.html">Peracetic Acid Sterilization</a></li>
		                         
                        <li><a href="../Disinfection_Sterilization/13_10otherSterilizationMethods.html">Other Sterilization Methods</a></li>
                        <li><a href="../Disinfection_Sterilization/13_11sterilizingPractices.html">Sterilizing Practices</a></li>
                    </ul>
                  </li>
                  <li><a href="../Disinfection_Sterilization/14_00ReuseMedicalDevices.html">Reuse of Single-Use Medical Devices</a></li>
                  <li><a href="../Disinfection_Sterilization/17_00Recommendations.html">Recommendations for Disinfection and Sterilization in Health-Care Facilities</a></li>
                  <li><a href="../Disinfection_Sterilization/18_00PerformanceIndicators.html">Performance Indicators</a></li>
                  <li><a href="../Disinfection_Sterilization/19_00glossary.html">Glossary</a></li>
                  <li><a href="../Disinfection_Sterilization/table_1.html">Tables &amp; Figure</a>
                    <ul>
                      <li><a href="../Disinfection_Sterilization/table_2.html">Table 2, 3</a></li>
                      <li><a href="../Disinfection_Sterilization/fig_1.html">Figure 1</a></li>
                      <li><a href="../Disinfection_Sterilization/table_4.html">Table 4</a></li>
                      <li><a href="../Disinfection_Sterilization/table_5.html">Table 5</a></li>
                      <li><a href="../Disinfection_Sterilization/table_6.html">Table 6</a></li>
                      <li><a href="../Disinfection_Sterilization/table_7.html">Table 7, 8, 9</a></li>
                      <li><a href="../Disinfection_Sterilization/table_10.html">Table 10, 11, 12</a></li>
                    </ul>
                  </li>
                  <li><a href="../Disinfection_Sterilization/20_00reference.html">References</a></li>
                </ul>
              </li>
	          <li><a href="../2007IP/2007isolationPrecautions.html">Guideline for Isolation Precautions 2007</a>
				  <ul>
                        <li><a href="../2007IP/2007ip_ExecSummary.html">Executive Summary</a></li>
                        <li> <a href="../2007IP/2007ip_part1.html">Part I: Review of Scientific Data Regarding Transmission of Infectious Agents in Healthcare Settings</a></li>
                        <li><a href="../2007IP/2007ip_part2.html">Part II: Fundamental elements needed to prevent transmission of infectious agents in healthcare settings</a></li>
                        <li><a href="../2007IP/2007ip_part3.html">Part III: Precautions to Prevent Transmission of Infectious Agents</a></li>
                        <li><a href="../2007IP/2007ip_part4.html">Part IV: Recommendations</a></li>
                        <li><a href="../2007IP/2007ip_appendA.html">Appendix A</a></li>
                        <li><a href="../2007IP/2007ip_tables.html">Tables 1 - 5</a>
                          <ul>
                            <li><a href="../2007IP/2007ip_table2.html">Table 2</a></li>
                            <li><a href="../2007IP/2007ip_table3.html">Table 3</a></li>
                            <li><a href="../2007IP/2007ip_table4.html">Table 4</a></li>
                            <li><a href="../2007IP/2007ip_table5.html">Table 5</a></li>
                          </ul>
                        </li>
                        <li><a href="../2007IP/2007ip_fig.html">Figure. Example of Safe Donning and Removal of PPE</a></li>
                        <li><a href="../2007IP/2007ip_glossary.html">Glossary</a></li>
                        <li><a href="../2007IP/2007ip_reference.html">References</a></li>
                </ul>
			  </li>
			    
	            <li><a href="../cauti/001_cauti.html">2009 CAUTI Guideline</a>
	              <ul>
	                <li><a href="../cauti/002_cauti_toc.html">Table of Contents</a>
	                  <!--<ul><li><a href="/hicpac/Disinfection_Sterilization/1_sumIntroMethTerms-levi.html">test</a></li></ul>-->
                    </li>
                      <li><a href="../cauti/02_cauti2009_abbrev.html">Abbreviations</a></li>
                      <li><a href="../cauti/003_cauti2009_execSum.html">I. Executive Summary</a></li>
                      <li><a href="../cauti/002_cauti_sumORecom.html">II. Summary of Recommendations</a></li>
                      <li><a href="../cauti/003_ImplementAudit.html">III. Implementation and Audit</a></li>
                      <li><a href="../cauti/004_furtherResearch.html">IV. Recommendations for Further Research</a></li>
                      <li><a href="../cauti/005_background.html">V. Background</a></li>
                      <li><a href="../cauti/006_scopePurpose.html">VI. Scope and Purpose</a></li>
                      <li><a href="../cauti/007_methods.html">VII. Methods</a></li>
                      <li><a href="../cauti/008_evidenceReview.html">VIII. Evidence Review</a></li>
                      <li><a href="../cauti/009_cauti2009_References.html">References</a></li>
                      <li><a href="../cauti/010_cauti2009_figs.html">Figures</a></li>
		          </ul>
              </li>
              
              <li><a href="../CAUTI_fastFacts.html">CAUTI Guideline Fast Facts</a></li>
              <li><a href="../uti_saint_video.html">Podcast: Dr. Sanjay Saint discusses CAUTIs</a></li>
              <li><a href="mdro_0.html">Management of MDRO's in Healthcare Settings</a>
	          <ul>
	            <li><a href="mdro_toc.html">Table of Contents</a></li>
	            <li><a href="mdro_1.html">Introduction</a></li>
	            <li><a href="mdro_2.html">Background</a></li>
	            <li><a href="mdro_3.html">Epidemiology of MDROs</a></li>
	            <li><a href="mdro_4.html">MDRO Prevention and Control</a></li>
	            <li><a href="mdro_4_1.html">Discussion</a></li>
	            <li><a href="mdro_5.html">Prevention of transmission of Multidrug Resistant Organisms </a></li>
	            <li><a href="mdro_table1.html">Tables 1-2</a></li>
	            <li><a href="mdro_table3.html">Table 3</a> </li>
	            <li><a href="mdro_glossary.html">Glossary - Multidrug-Resistant Organisms</a></li>
	            <li><a href="mdro_reference.html">References</a></li>
              </ul>
	        </li>
	        <li><a href="../pubReportGuide/publicReportingHAI.html">Guidance on Public Reporting of HAIs 2003</a>
			      <ul>
			        <li><a href="../pubReportGuide/prg_tbl1.html">Table 1</a></li>
		            <li><a href="../pubReportGuide/prg_tbl2.html">Table 2</a></li>
                    <li><a href="../pubReportGuide/prHAI_reference.html">Reference</a></li>
	              </ul>
		      </li>
            <li><a href="../SSI/001_SSI.html">Guideline for Prevention of Surgical Site Infection, 1999 </a>
              <ul>
                <li><a href="../SSI/toc_SSI.html"> Table of contents</a></li>
                
                <li><a href="../SSI/002_SSI.html">Surgical Site Infection (SSI): An Overview</a></li>
                <li><a href="../SSI/003_SSI.html">Microbiology</a></li>
                <li><a href="../SSI/004_SSI.html"> Operative characteristics: Preoperative issues                                 </a></li>
                <li><a href="../SSI/005_SSI.html">Operative characteristics: Intraoperative issues 
                                 </a></li>
                <li><a href="../SSI/006_SSI.html">SSI Surveillance </a></li>
                <li><a href="../SSI/007_SSI.html">Recommendations for Prevention of SSI</a></li>
                <li><a href="../SSI/ref-SSI.html">References </a></li>
                <li><a href="../SSI/figure-SSI.html">Figure</a></li>
                <li><a href="../SSI/table1-SSI.html">Table 1</a></li>
                <li><a href="../SSI/table2-SSI.html">Table 2</a></li>
                <li><a href="../SSI/table3-SSI.html">Table 3</a></li>
                <li><a href="../SSI/table4-SSI.html">Table 4</a></li>
                <li><a href="../SSI/table5-SSI.html">Table 5</a></li>
                <li><a href="../SSI/table6-SSI.html">Table 6</a></li>
                <li><a href="../SSI/table7-8-9-10-SSI.html">Table 7-8-9-10</a></li>
              </ul>
            </li>
            <li><a href="../Pubs/Antibiotic-Stewardship-Statement.html">Antibiotic Stewardship Statement for Antibiotic Guidelines, 2016</a></li>
      </ul>
	  </li>
       
	<li><a href="../presentations.html">Proceedings &amp; Presentations</a>
	  <!--ul>
	    <li><a href="/hicpac/transcript-07-23.html">July 09 - Interim Guidance for Care of Patients with Confirmed /Suspected 2009 H1N1</a></li>
        <li><a href="/hicpac/h1n12009.html">Summary of Recommendations for Care of Patients with Confirmed /Suspected 2009 H1N1</a></li>
	  </ul-->
	</li>
   
    <!--li><a href="/hicpac/registration.html">HICPAC Online Registration</a></li-->
    <li><a href="../contact.html">Contact HICPAC</a></li>
  </ul>
</div>
<div class="bottom"></div>

			  
             
				<!-- InstanceEndEditable -->
			</div>
			
		<!-- /end #content --></div>
		
		<div class="preFoot">
			<div id="plugin-legend">
			<h3>File Formats Help:</h3>
			<ul>
				<li class="plugin-pdf"><a href="../../Other/plugins/index.html#pdf"><img src="../../TemplatePackage/images/icon_pdf.gif" alt="Adobe PDF file" /></a></li>
				<li class="plugin-word"><a href="../../Other/plugins/index.html#doc"><img src="../../TemplatePackage/images/icon_word.gif" alt="Microsoft Word file" /></a></li>
				<li class="plugin-excel"><a href="../../Other/plugins/index.html#xls"><img src="../../TemplatePackage/images/icon_excel.gif" alt="Microsoft Excel file" /></a></li>
				<li class="plugin-ppt"><a href="../../Other/plugins/index.html#ppt"><img src="../../TemplatePackage/images/icon_ppt.gif" alt="Microsoft PowerPoint file" /></a></li>
				<li class="plugin-wmv"><a href="../../Other/plugins/index.html#wmv"><img src="../../TemplatePackage/images/icon_wmv.gif" alt="Audio/Video file" /></a></li>
				<li class="plugin-zip"><a href="../../Other/plugins/index.html#zip"><img src="../../TemplatePackage/images/icon_zip.gif" alt="Zip Archive file" /></a></li>
				<li class="plugin-real"><a href="../../Other/plugins/index.html#ram"><img src="../../TemplatePackage/images/icon_real.gif" alt="RealPlayer file" /></a></li>
				<li class="plugin-qt"><a href="../../Other/plugins/index.html#qt"><img src="../../TemplatePackage/images/icon_qt.gif" alt="Apple Quicktime file" /></a></li>
			</ul>
			<p><a href="../../Other/plugins/index.html"><span class="tp-label">How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?</span>&nbsp;<img src="../../TemplatePackage/images/btn_dblArrows.gif" alt="double arrows." /></a></p>
		</div>
			<div class="pageOptions-horizontal">
				<ul class="services">
					<li class="print"><a href="javascript:window.print();">Print</a></li>
<!-- InstanceBeginEditable name="local-options-horizontal" -->
				<!--<li class="pdf"><a href="">Download</a></li>-->
				 
				<!--<li class="rss"><a href="">Subscribe</a></li>-->
				<!-- InstanceEndEditable -->
				</ul>
			</div>
			<div id="datestamp"><!-- InstanceBeginEditable name="date-stamp" -->
			<ul>
				<li class="last-reviewed">Page last reviewed: <span>December 29, 2009</span></li>
				<li class="last-updated">Page last updated: <span>December 29, 2009</span></li>
				<li class="content-source">Content source: <a href="../../index.html">Centers for Disease Control and Prevention</a></li>
                 <li class="content-source"><a href="https://www.cdc.gov/ncpdcid/">National Center for Preparedness, Detection, and Control of Infectious Diseases (NCPDCID)</a></li>
        <li class="content-source"><a href="https://www.cdc.gov/ncidod/dhqp/index.html">Division of Healthcare Quality Promotion (DHQP) </a></li>
		</ul>
		<!-- InstanceEndEditable -->
			</div>
			
		</div>
		<div id="siteinfo">
	<div id="siteinfo-nav">
		<ul class="menu">
			<li><a href="../../index.html">Home</a></li>
			<li><a href="../../az/a.html">A-Z Index</a></li>
			<li><a href="../../Other/policies.html">Policies</a></li>
			<li><a href="../../Other/about_cdcgov.html">Using this Site</a></li>
			<li><a href="../../Other/link.html">Link to Us</a></li>
			<li class="last-child"><a href="../../contact.1.html">Contact CDC</a></li>
		</ul>
	</div>
	<div id="siteinfo-credits">
		<div id="siteinfo-logos"><a href="https://www.usa.gov//"><img id="logo_usagov" src="../../TemplatePackage/images/logo_usagov.gif" alt="USA.gov: The U.S. Government's Official Web Portal" width="188" height="55" border="0" /></a><a href="https://www.hhs.gov/"><img id="logo_dhhs" src="../../TemplatePackage/images/logo_dhhs.gif" alt="Department of Health and Human Services" width="61" height="55" border="0" /></a></div>
		<address>Centers for Disease Control and Prevention &nbsp; 1600 Clifton Road Atlanta, GA 30329-4027, USA<br />
		800-CDC-INFO (800-232-4636)	TTY: (888) 232-6348 - <a href="https://wwwn.cdc.gov/dcs/RequestForm.aspx">Contact CDC&ndash;INFO</a></address>
	</div>
</div>

<!--include virtual="/TemplatePackage/3.0/includes/interstitialModal.html" -->
		
		<div id="AZlist-container"><a name="az"></a>
	<span>A-Z Index</span>
	<ol class="AZlist">
		<li><a href="../../az/a.html">A</a></li>
		<li><a href="../../az/b.html">B</a></li>
		<li><a href="../../az/c.html">C</a></li>
		<li><a href="../../az/d.html">D</a></li>
		<li><a href="../../az/e.html">E</a></li>
		<li><a href="../../az/f.html">F</a></li>
		<li><a href="../../az/g.html">G</a></li>
		<li><a href="../../az/h.html">H</a></li>
		<li><a href="../../az/i.html">I</a></li>
		<li><a href="../../az/j.html">J</a></li>
		<li><a href="../../az/k.html">K</a></li>
		<li><a href="../../az/l.html">L</a></li>
		<li><a href="../../az/m.html">M</a></li>
		<li><a href="../../az/n.html">N</a></li>
		<li><a href="../../az/o.html">O</a></li>
		<li><a href="../../az/p.html">P</a></li>
		<li><a href="../../az/q.html">Q</a></li>
		<li><a href="../../az/r.html">R</a></li>
		<li><a href="../../az/s.html">S</a></li>
		<li><a href="../../az/t.html">T</a></li>
		<li><a href="../../az/u.html">U</a></li>
		<li><a href="../../az/v.html">V</a></li>
		<li><a href="../../az/w.html">W</a></li>
		<li><a href="../../az/x.html">X</a></li>
		<li><a href="../../az/y.html">Y</a></li>
		<li><a href="../../az/z.html">Z</a></li>
		<li><a href="../../az/0.html">#</a></li>
	</ol>
</div>

	<!-- /end #wrapper-inner --></div>
	
<!-- /end #wrapper --></div>

<!-- xxxxxxxxxxxxxxxxxx METRICS code begins here xxxxxxxxxxxxxxxxxxxxxxxxxxx-->
<div id="metrics">

<!-- Begin Google DAP inclusion -->
<script type="text/javascript" id="_fed_an_ua_tag" src="../../JScript/metrics/google/Universal-Federated-Analytics-Min.js@agency=HHS&amp;subagency=CDC"></script>
<!-- End Google DAP inclusion -->

<!-- SiteCatalyst code version: H.21. -->
<script language="JavaScript" type="text/javascript" src="../../JScript/metrics/topic_levels.js"></script>
<script language="JavaScript" type="text/javascript" src="../../JScript/metrics/s_code_v21_cdcgov.js"></script>
<script language="JavaScript" type="text/javascript">

<!-- InstanceBeginEditable name="metrics" -->
s.pageName=document.title;
s.channel="HICPAC";

siteCatalyst.setLevel1("NCEZID"); 
siteCatalyst.setLevel2("DHQP"); 
siteCatalyst.setLevel3("Healthcare Infection Control Practices Advisory Committee"); 
<!-- InstanceEndEditable -->
s.prop2=window.location.href;
s.prop26=document.title;
s.prop30=document.title;
s.prop31=window.location.href;
s.prop46=window.location.href;
s.server=window.location.hostname;

// Update the level variables here.
updateVariables(s);

/************* DO NOT ALTER ANYTHING BELOW THIS LINE ! **************/
var s_code=s.t();if(s_code)document.write(s_code);//--></script>
<script language="JavaScript" type="text/javascript"><!--
if(navigator.appVersion.indexOf('MSIE')>=0)document.write(unescape('%3C')+'\!-'+'-');
//--></script><noscript><a href="http://www.omniture.com" title="Web Analytics"><img src="https://smtrics.cdc.gov/b/ss/cdcgov/1/H.21--NS/01/H.21--NS/0" height="1" width="1" border="0" alt="Web Analytics" /></a></noscript><!--/DO NOT REMOVE/-->
<!-- End SiteCatalyst code version: H.21. -->
<!-- Begin Template Package Custom Interactions -->
<script type="text/javascript" src="../../JScript/metrics/rd_custom_interactions.js"></script>
<!-- End Template Package Custom Interactions -->
<!-- Begin Template Package DigitalGov Search Support -->
<script type="text/javascript" src="../../JScript/rd_search.js"></script>
<!-- End Template Package DigitalGov Search Support -->
</div>
<!-- xxxxxxxxxxxxxxxxxx METRICS code ends here xxxxxxxxxxxxxxxxxxxxxxxxxxx-->



</body>
<!-- InstanceEnd --></html>